Vaginal DNA Assay Shows Promise

A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.

By
Kerri Miller
May 8, 2026
14 min

Conexiant

At a Glance

Category	Detail
Condition
Key Mechanisms
Target Population	Women aged 45 years and older with abnormal uterine bleeding, and younger patients with specific risk factors.
Care Setting

Key Highlights

96% sensitivity and 82% specificity for detecting endometrial cancer (from a case-control study, not directly applicable to clinical rule-out).
Utilizes self-collected vaginal fluid samples via unscented tampons.
Addresses limitations of current diagnostic methods like endometrial biopsy and dilation and curettage.

Guideline-Based Recommendations

Diagnosis

Endometrial sampling recommended for patients aged 45 and older with abnormal uterine bleeding.

Management

Further validation in real-world populations needed before clinical implementation.

Monitoring & Follow-up

Assess negative predictive value in broader populations.

Risks

Current diagnostic methods carry procedural burdens and risks.

Patient & Prescribing Data

Assay shows promise but requires further validation before clinical use.

Clinical Best Practices

Consider the assay as a supplementary tool pending further validation.
Use existing guidelines for endometrial sampling in appropriate patient populations.